Brief: Betterlife Receives FDA Response On Its Pre-Ind Application For Major Depressive Disorder (Mdd) Treatment With Betr-001
20/01/2022 13:22
Jan 20 (Reuters) - BetterLife Pharma Inc BETR.CD :
* BETTERLIFE RECEIVES FDA RESPONSE ON ITS PRE-IND
APPLICATION FOR
MAJOR DEPRESSIVE DISORDER (MDD) TREATMENT WITH BETR-001
Source text for Eikon: ID:nGNX7rVBdH
Further company coverage: BETR.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BetterLife Pharma
See all newsBrief: Betterlife Pharma Provides Scientific Update On Neuroplastogenic Activity Of BETR-001
Brief: Betterlife Pharma Advanced In IND-enabling Studies For BETR-001
Brief: BetterLife Announces Closing Of $1.168 Million Convertible Debentures To Further Advance IND-Enabling Studies Of Its Non-Hallucinogenic LSD-Based Drug Candidate BETR-001
Brief: Omineca Announces $2 Mln Brokered Financing Of Flow-Through Units
Brief: Betterlife Announces Pricing Of Proposed Offering Of Units